PDS Biotechnology Corporation - PDSB STOCK NEWS

PDS Biotechnology Corporation (Nasdaq: PDSB) reported Q3 2020 financial results, revealing a net loss of approximately $3.9 million, or $0.23 per share, a decrease from a $5.8 million loss in Q3 2019. R&D expenses rose by 12% to $2.1 million, while general and administrative costs dropped by 40% to $1.8 million. The company successfully raised $19 million in a public offering and initiated several Phase 2 trials for its investigational drug PDS0101. As of September 30, 2020, cash reserves stood at $33.5 million.

PDS Biotech has prioritized the clinical development of PDS0203, a Versamune®-based COVID-19 vaccine, following a successful meeting with Brazil's drug regulatory agency, ANVISA. The vaccine aims to elicit strong immune responses, showing a 30-45 fold increase in T-cell activation compared to standard vaccines. PDS Biotech and Farmacore plan to begin human trials in the first half of 2021, backed by promising preclinical data. Both companies will collaborate on regulatory efforts, with Farmacore leading in Brazil.

PDS Biotechnology Corporation has launched the VERSATILE-002 Phase 2 trial, assessing the combination of PDS0101 and KEYTRUDA® for first-line treatment of recurrent or metastatic head and neck cancer. This multi-center trial aims to enroll around 100 patients across 25 sites in the U.S., with the University of Tennessee Medical Center as the first site. The study evaluates the efficacy and safety of PDS0101, targeting HPV-associated cancers. The primary endpoint is the objective response rate at nine months. This trial marks a significant step in the collaboration with Merck.

PDS Biotechnology Corporation (Nasdaq: PDSB) announced the appointment of Dr. Otis Brawley to its Board of Directors. Dr. Brawley, an esteemed oncologist with extensive experience in oncology and pharmaceutical development, is currently the Bloomberg Distinguished Professor at Johns Hopkins University. His past roles include Chief Medical and Scientific Officer at the American Cancer Society and member of the FDA Oncologic Drug Advisory Committee. The company highlights that Dr. Brawley's expertise will be crucial as PDS Biotech advances its clinical programs.

PDS Biotechnology Corporation (Nasdaq: PDSB) has announced its participation in the "Grand Rounds: a Webinar in Biotech and Specialty Pharma" on November 2, 2020, hosted by Alliance Global Partners. This presentation will showcase the company's proprietary Versamune^® technology used in cancer therapies and infectious disease vaccines.

The company will also report its third quarter 2020 financial results on November 11, 2020, followed by a conference call on November 12, 2020, at 8:00 am Eastern Time to discuss the results and provide a business update.

PDS Biotech has initiated a Phase 2 clinical trial for PDS0101 combined with standard chemoradiotherapy (CRT) to treat locally advanced cervical cancer. The study, led by MD Anderson Cancer Center, will evaluate the safety and anti-tumor efficacy of this combination in approximately 35 patients. The trial aims to correlate the treatment’s effectiveness with biomarkers of immune response. Dr. Lauren Wood, the Chief Medical Officer, expresses optimism regarding the potential of PDS0101 in enhancing cervical cancer treatments.

PDS Biotechnology Corporation (PDSB), a clinical-stage immunotherapy firm, announced the virtual presentations of its CEO, Frank Bedu-Addo, at notable investment conferences. The H.C. Wainwright & Co. 22nd Annual Global Investment Conference is set for September 16, 2020, at 2:30 PM ET, and the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit is on September 23, 2020, at 4:10 PM ET. The company specializes in innovative cancer therapies and vaccines, utilizing its proprietary Versamune® technology. A replay of the Oppenheimer presentation will be available for 90 days.

PDS Biotechnology Corporation (NASDAQ: PDSB), a clinical-stage immunotherapy company, participated in Noble Capital Markets’ C-Suite Interview Series on August 21, 2020. CEO Frank Bedu-Addo discussed key topics including the status of the PDS0101 oncology candidate, which is undergoing three Phase 2 clinical trials, and the company’s growing portfolio, targeting various cancers and infectious diseases like COVID-19 and the flu. The interview also touched on financial metrics, including current cash position and anticipated value-generating catalysts for the next year.

PDS Biotechnology Corporation (Nasdaq: PDSB) has successfully closed its underwritten public offering of 6,900,000 shares of common stock at a price of $2.75 per share, yielding approximately $19.0 million in gross proceeds. The offering included 900,000 additional shares exercised by the underwriter. Several company insiders participated in the purchase. The shares were offered under a registration statement filed with the SEC. This initiative is aimed at enhancing the company's financial position as it advances its proprietary Versamune® T-cell activating technology for cancer therapies and vaccines.